RenovoRx Q2 net loss holds at $2.91 million; revenue more than doubled to $909,000 year over year

Reuters2026/08/12 20:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

RenovoRx posted Q2 revenue of USD 909,000, up 61% sequentially, with gross margin of about 84%.
Net loss was USD 2.9 million, little changed year over year; loss per share narrowed to USD 0.06.
SG&A climbed to USD 2.9 million; R&D eased to USD 1.2 million.
Raised 2026 revenue guidance to USD 3.75 million-USD 4.25 million, citing accelerating commercial adoption and repeat ordering.
Ended Q2 with 21 active commercial cancer centers; Phase III TIGeR-PaC trial reached full enrollment, with topline data expected in H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808984) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

RenovoRx Q2 net loss holds at $2.91 million; revenue more than doubled to $909,000 year over year

You may also like

Crypto prices